Axsome Therapeutics, Inc. (LON:0HKF)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 5.10B -3.7% |
| Revenue (ttm) | 651.75M +54.2% |
| Net Income | -118.48M |
| EPS | -2.29 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 62.96 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 411 |
| Open | 134.00 |
| Previous Close | 133.38 |
| Day's Range | 132.00 - 142.98 |
| 52-Week Range | 123.16 - 263.93 |
| Beta | 0.83 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 2, 2026 |
About Axsome Therapeutics
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago... [Read more]
Financial Performance
In 2025, Axsome Therapeutics's revenue was $638.50 million, an increase of 65.55% compared to the previous year's $385.69 million. Losses were -$183.17 million, -36.22% less than in 2024.
Financial numbers in USD Financial StatementsNews
Axsome Therapeutics Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
Q3 revenue reached $260M, with AUVELITY up 53% YoY and agitation NBRXs rising 3.6x after approval. Management highlighted continued commercial investment, a May 1 PDUFA for AXS-12 and multiple potential 2027 pipeline catalysts.
Axsome Therapeutics price target lowered to $272 from $284 at Mizuho
Mizuho lowered the firm’s price target on Axsome Therapeutics (AXSM) to $272 from $284 and keeps an Outperform rating on the shares.
Axsome Therapeutics price target lowered to $245 from $267 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Axsome Therapeutics (AXSM) to $245 from $267 and keeps a Buy rating on the shares following the Q3 report. Published first on…
Axsome Therapeutics price target raised to $249 from $247 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Axsome Therapeutics (AXSM) to $249 from $247 and keeps an Equal Weight rating on the shares.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
NEW YORK, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...
Axsome Therapeutics price target lowered to $250 from $275 at Guggenheim
Guggenheim analyst Yatin Suneja lowered the firm’s price target on Axsome Therapeutics (AXSM) to $250 from $275 and keeps a Buy rating on the shares as the firm adjusted estimates…
BofA trims Axsome Therapeutics price target, says selloff overdone
BofA lowered the firm’s price target on Axsome Therapeutics (AXSM) to $264 from $276 and keeps a Buy rating on the shares. Q3 was largely in-line, but shares continue to…
Axsome Therapeutics price target lowered to $220 from $246 at Baird
Baird lowered the firm’s price target on Axsome Therapeutics (AXSM) to $220 from $246 and keeps an Outperform rating on the shares. The firm updated its model following solid results…
Axsome Therapeutics price target lowered to $273 from $295 at RBC Capital
RBC Capital analyst Leonid Timashev lowered the firm’s price target on Axsome Therapeutics (AXSM) to $273 from $295 but keeps an Outperform rating on the shares. The company reported its…
Axsome Therapeutics price target lowered to $239 from $256 at UBS
UBS analyst Ashwani Verma lowered the firm’s price target on Axsome Therapeutics (AXSM) to $239 from $256 and keeps a Buy rating on the shares. The stock sold off following…
Axsome shares ‘significantly undervalued,’ says TD Cowen
TD Cowen analyst Joseph Thome reiterated a Buy rating and $135 price target on Axsome Therapeutics (AXSM) after the company reported Q3 revenue that rose 52% year-over-year, led by $208M…
Axsome Therapeutics price target lowered to $305 from $380 at Jefferies
Jefferies lowered the firm’s price target on Axsome Therapeutics (AXSM) to $305 from $380 and keeps a Buy rating on the shares. For Q3, Auvelity’s sales in depression and Alzheimer’s…
Axsome Therapeutics price target lowered to $235 from $238 at Piper Sandler
Piper Sandler analyst David Amsellem lowered the firm’s price target on Axsome Therapeutics (AXSM) to $235 from $238 and keeps an Overweight rating on the shares. The firm reduced estimates…
Axsome Therapeutics reports Q3 EPS (25c), consensus (56c)
Reports Q3 revenue $259.69M, consensus $249.93M. “Axsome delivered 52% year-over-year total revenue growth in the third quarter, surpassing a one-billion-dollar annual run rate. We expect sustained mo...
Axsome Therapeutics falls -10.9%
Axsome Therapeutics (AXSM) is down -10.9%, or -$15.74 to $128.69.
Axsome Therapeutics Earnings Call Transcript: Q3 2026
Q3 revenue rose 52% YoY to $259.7M, with AUVELITY leading commercial growth and net loss narrowing to $12.9M. Pipeline programs advanced, with several 2027 clinical and regulatory milestones ahead.
Axsome Therapeutics Earnings release: Q3 2026
Axsome Therapeutics released its Q3 2026 earnings on November 2, 2026, summarizing the period's financial results.
Axsome Therapeutics Slides: Q3 2026
Axsome Therapeutics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 2, 2026.
Axsome Therapeutics Quarterly report: Q3 2026
Axsome Therapeutics has published its Q3 2026 quarterly earnings report on November 2, 2026.
Axsome Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Total 3Q 2026 net product revenue of $259.7 million, representing 52% year-over-year growth AUVELITY ® 3Q 2026 net product sales of $207.6 million, representing 53% year-over-year growth SUNOSI ® 3Q 2...
Axsome Therapeutics price target lowered to $284 from $316 at Mizuho
Mizuho analyst Graig Suvannavejh lowered the firm’s price target on Axsome Therapeutics (AXSM) to $284 from $316 and keeps an Outperform rating on the shares.
Axsome Therapeutics price target lowered to $238 from $258 at Piper Sandler
Piper Sandler lowered the firm’s price target on Axsome Therapeutics (AXSM) to $238 from $258 and keeps an Overweight rating on the shares. The firm is reviewing the Q3 cycle…
Axsome Therapeutics price target lowered to $295 from $297 at RBC Capital
RBC Capital lowered the firm’s price target on Axsome Therapeutics (AXSM) to $295 from $297 and keeps an Outperform rating on the shares as part of a broader research note…
Axsome Therapeutics to Report Third Quarter 2026 Financial Results on November 2
NEW YORK, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...
Axsome Therapeutics price target lowered to $267 from $280 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Axsome Therapeutics (AXSM) to $267 from $280 and keeps a Buy rating on the shares. The firm updated its estimates for Auvelity…